StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.11+0.12 (+0.75%)

Close on Nov 17, 2026Market cap $2.98BP/E –Yield –

Legend Biotech gross margin

Gross margin is gross profit as a percentage of revenue.

Legend Biotech's gross margin for the twelve months ending Jun 30, 2026 was 57.2%. For fiscal 2025 it was 61.4%, against 65.5% the year before. The highest annual figure on record is 100.0% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202561.4%−4.1
FY2024Dec 31, 202465.5%+16.1
FY2023Dec 31, 202349.4%+5.3
FY2022Dec 31, 202244.1%−55.9
FY2021Dec 31, 2021100.0%+0.0
FY2020Dec 31, 2020100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202664.9%+2.1
Q1 FY2026Mar 31, 202642.5%−21.8
Q4 FY2025Dec 31, 202561.0%−1.8
Q3 FY2025Sep 30, 202558.4%−8.8
Q2 FY2025Jun 30, 202562.8%−12.9
Q1 FY2025Mar 31, 202564.4%+16.6
Q4 FY2024Dec 31, 202462.8%+3.6
Q3 FY2024Sep 30, 202467.2%+12.5
Q2 FY2024Jun 30, 202475.7%+20.2
Q1 FY2024Mar 31, 202447.8%+45.8
Q4 FY2023Dec 31, 202359.2%+42.3
Q3 FY2023Sep 30, 202354.7%+47.8
Q2 FY2023Jun 30, 202355.4%–
Q1 FY2023Mar 31, 20232.0%–
Q4 FY2022Dec 31, 202216.9%–
Q3 FY2022Sep 30, 20226.9%–

More Legend Biotech figures

See a number that looks wrong?